U.S. markets closed

Longevity Acquisition Corporation (LOACU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
14.330.00 (0.00%)
At close: 2:02PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close14.33
Open14.33
Bid9.51 x 3000
Ask15.77 x 1100
Day's Range14.33 - 14.33
52 Week Range10.25 - 20.50
Volume120
Avg. Volume404
Market Cap25.229M
Beta (5Y Monthly)0.03
PE Ratio (TTM)N/A
EPS (TTM)-0.36
Earnings DateJan 08, 2021 - Jan 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Longevity Acquisition Corp. - LOAC
      PR Newswire

      SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Longevity Acquisition Corp. - LOAC

      Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Longevity Acquisition Corp. ("LOAC" or the "Company") (LOAC) relating to its proposed merger with 4D Pharma PLC. Under the terms of the agreement, LOAC shareholders will receive 7.5315 shares of 4D Pharma per share.

    • Longevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
      PR Newswire

      Longevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

      Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on February 8, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Live Biotherapeutic products ("LBPs") - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for BAVENCIO® (avelumab), the first and only immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma. BAVENCIO is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc.

    • Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
      PR Newswire

      Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program

      Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on February 3, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Live Biotherapeutic products ("LBPs") - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has announced progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518.